Table 3.
Patient irAE characteristics and incidence rates of infection for patients included in the analysis.
| Study information | Type of irAE | Treatment for irAE | Follow up | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| First author and year | Patientsn | GIn (%) | Hepatobiliaryn (%) | Lungn (%) | Steroids n (%) | Median steroids dose (mg) | IFX n (%) | VDZn (%) | Infection rate n (%) | Duration (mons) |
| Alexander 2021 | 127 | 127 (100) | 0 (0) | 0 (0) | 127 (100) | > 5 mg | 127 (100) | 127 (100) | 26 (20.5) | 6 |
| Au 2018 | 57 | 0 (0) | 57 (100) | 0 (0) | 45 (78.9) | 1.3 mg/kg | 0 (0) | 0 (0) | 15 (26.3) | 4 |
| Beattie 2020 | 26 | 0 (0) | 0 (0) | 26 (100) | 26 (100) | 100 mg | 20 (76.9) | 0 (0) | 4 (15.4) | 2 |
| Johnson 2018 | 75 | 75 (100) | 0 (0) | 0 (0) | 75 (100) | NR | 36 (48) | 0 (0) | 2 (2.7) | 26 |
| Kadokawa 2021 | 8 | 7 (87.5) | 1 (12.5) | 0 (0) | 8 (100) | NR | 8 (100) | 0 (0) | 4 (50) | 3 |
| Li 2022 | 215 | 55 (25.6) | 215 (100) | 58 (27.0) | 215 (100) | NR | 0 (0) | 0 (0) | 25 (11.6) | NR |
| Shah 2022 | 112 | 48 (42.9) | 28 (25) | 23 (20.5) | 112 (100) | >20 mg | 15 (13.4) | 3 (2.7) | 22 (19.6) | 3 |
| Thompson 2021‡ | 50 | 0 (0) | 0 (0) | 0 (0) | 50 (100) | NR | 0 (0) | 0 (0) | 17 (34) | 3 |
| Wang 2018 | 79 | 79 (100) | 0 (0) | 0 (0) | 79 (100) | NR | 35 (44.3) | 0 (0) | 29 (36.7) | 1 |
| Williams 2019 | 103 | 0 (0) | 0 (0) | 28 (27.2) | 103 (100) | 1mg/kg | 0 (0) | 0 (0) | NR | 3 |
| Zou 2021 | 184 | 184 (100) | 0 (0) | 0 (0) | 184 (100) | NR | 94 (51.1) | 63 (34.2) | 35 (19.0) | 45 |
GI, gastrointestinal; IFX, infliximab; irAE, immune-related adverse event; NR, not reported; VDZ, vedolizumab.
‡Our analysis for this study was limited to those who received systemic corticosteroids.